1. Home
  2. SBLX vs AZTR Comparison

SBLX vs AZTR Comparison

Compare SBLX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SBLX

StableX Technologies Inc.

HOLD

Current Price

$3.11

Market Cap

3.7M

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.19

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBLX
AZTR
Founded
2017
2014
Country
United States
United States
Employees
58
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.5M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
SBLX
AZTR
Price
$3.11
$0.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
10.1M
455.5K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.64
$0.10
52 Week High
$7.85
$1.40

Technical Indicators

Market Signals
Indicator
SBLX
AZTR
Relative Strength Index (RSI) 68.25 30.74
Support Level $2.83 $0.15
Resistance Level $3.11 $0.26
Average True Range (ATR) 0.43 0.02
MACD 0.06 -0.01
Stochastic Oscillator 36.89 11.26

Price Performance

Historical Comparison
SBLX
AZTR

About SBLX StableX Technologies Inc.

StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: